Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Astrazeneca Plc Ord
(OP:
AZNCF
)
175.00
+2.98 (+1.73%)
Streaming Delayed Price
Updated: 10:26 AM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Astrazeneca Plc Ord
< Previous
1
2
3
4
5
6
7
8
Next >
AstraZeneca To Offload Some Drug Rights To Covis Pharma For $270M
November 01, 2021
AstraZeneca Plc (NASDAQ: AZN) will transfer global rights for respiratory medicines Eklira and Duaklir to Covis Pharma Group for $270 million. Covis will also...
Via
Benzinga
AstraZeneca's Imfinzi/Chemo Combo Strikes First Immunotherapy Wins In Bile Duct Cancer Trial
October 26, 2021
AstraZeneca Plc (NASDAQ: AZN) revealed topline results from the Phase 3 TOPAZ-1 study. Related: AstraZeneca Touts Longest Survival Update In Lung Cancer...
Via
Benzinga
AstraZeneca Pulls Plug On MCL-1 Cancer Drug Trial
October 20, 2021
AstraZeneca Plc (NASDAQ: AZN) has paused an active Phase 1 trial of AZD5991, a direct inhibitor of MCL-1, citing a potential safety issue. Two years ago, the FDA hit ...
Via
Benzinga
Exposures
Product Safety
AstraZeneca's COVID-19 Therapy Hits Goal In Phase 3 Trial
October 11, 2021
AstraZeneca Plc (NASDAQ: AZN) released top-line data from the TACKLE Phase 3 trial in which its experimental COVID-19 drug has helped cut the risk of severe disease...
Via
Benzinga
Exposures
COVID-19
AstraZeneca Seeks Emergency Use Nod For COVID-19 Drug To Prevent Infection
October 05, 2021
AstraZeneca Plc (NASDAQ: AZN) has filed for an FDA Emergency Use Authorization (EUA) of AZD7442, its long-acting antibody (LAAB) combination, for prophylaxis of...
Via
Benzinga
Exposures
COVID-19
Product Safety
EMA's Risk Assessment Committee Finds Link Of Rare Cases Between JNJ COVID-19 Shot, Blood Clots
October 01, 2021
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) has concluded a possible link to rare cases of venous thromboembolism (VTE) with...
Via
Benzinga
Exposures
COVID-19
AstraZeneca COVID-19 Jab Shows 74% Efficacy In US Trial
September 30, 2021
Reuters reported that large U.S. trial results of AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine demonstrated 74% efficacy at preventing symptomatic disease...
Via
Benzinga
Exposures
COVID-19
Adagio's COVID-19 Candidate Shows Prolonged Half-Life, Neutralization At Six Months
September 29, 2021
Adagio Therapeutics Inc (NASDAQ: ADGI) has announced new data from its COVID-19 antibody program. Related Link: Adagio Therapeutics To Expand Late-Stage...
Via
Benzinga
Exposures
COVID-19
AstraZeneca Buys Fortress-Biotech Founded Caelum For $500M
September 29, 2021
AstraZeneca Plc (NASDAQ: AZN) will take complete control of Caelum Biosciences in a deal worth up to $500 million, sharpening its focus on rare-disease...
Via
Benzinga
AstraZeneca's Saphnelo For Lupus Treatment Approved In Japan
September 28, 2021
The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved AstraZeneca plc’s (NASDAQ: AZN) Saphnelo (anifrolumab) for systemic lupus...
Via
Benzinga
AstraZeneca, Sputnik Light COVID-19 Vaccine Mix Shows Strong Antibody Growth: Reuters
September 27, 2021
A small-scale study of AstraZeneca Plc (NASDAQ: AZN) COVID-19 combined with Sputnik Light vaccines has shown robust antibody growth in most of the study's...
Via
Benzinga
Exposures
COVID-19
AstraZeneca - Merck's Lynparza Delays Disease Progression In Prostate Cancer Patients
September 24, 2021
AstraZeneca Plc (NASDAQ: AZN) has reported high-level results from the PROpel Phase 3 trial of Lynparza (olaparib) in metastatic castration-resistant prostate...
Via
Benzinga
AstraZeneca Invests In Imperial College's Self-Amplifying RNA Tech
September 23, 2021
AstraZeneca Plc (NASDAQ: AZN) struck a deal with a startup for a self-amplifying RNA (saRNA) therapeutics platform developed at Imperial College London. Under the...
Via
Benzinga
AstraZeneca To Inject $360M In Irish API Manufacturing Site
September 21, 2021
AstraZeneca plc (NASDAQ: AZN) will invest $360 million to develop a manufacturing facility in Ireland to produce active pharmaceutical ingredients (APIs). The...
Via
Benzinga
AstraZeneca's Enhertu Posts Substantial Clinical Benefit Over Roche's Kadcyla In Breast Cancer Trials
September 20, 2021
AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo's (OTC: DSNKY) Enhertu have shown some striking data in late-stage breast cancer trials and early solid tumor...
Via
Benzinga
AstraZeneca Touts Longest Survival Update In Lung Cancer Setting With Imfinzi/Chemo Data
September 20, 2021
AstraZeneca plc (NASDAQ: AZN) announced updated data from the CASPIAN Phase 3 trial of Imfinzi (durvalumab) combined with a choice of chemotherapies etoposide plus...
Via
Benzinga
AstraZeneca's Imfinzi / Tremelimumab Combo Regime Shows Survival Benefit In Lung Cancer Settings
September 09, 2021
POSEIDON Phase 3 trial results showed AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab), tremelimumab, and chemotherapy, extended survival in lung cancer...
Via
Benzinga
Amgen, AstraZeneca Tout Additional Data From Asthma Trial With Tezepelumab
September 07, 2021
Amgen Inc (NASDAQ: AMGN) announced new data from the NAVIGATOR Phase 3 trial evaluating tezepelumab in patients who also have nasal polyps, a common complication...
Via
Benzinga
Why Innate Pharma Shares Are Rising On Friday?
September 03, 2021
Innate Pharma SA (NASDAQ:IPHA) stock closed a...
Via
Benzinga
AstraZeneca's Ultomiris Scores European Nod For Rare Blood Disorder In Kids, Adolescents
September 03, 2021
The European Commission has approved Alexion's Ultomiris (ravulizumab) paroxysmal nocturnal hemoglobinuria (PNH) in children (with a bodyweight of 10 kg or above)...
Via
Benzinga
AstraZeneca, EU Reach Settlement On COVID-19 Vaccine Delivery
September 03, 2021
AstraZeneca Plc (NASDAQ: AZN) and the European Commission have settled on the delivery of pending COVID-19 vaccine doses by the Company. The agreement ends legal...
Via
Benzinga
Exposures
COVID-19
AstraZeneca's Drug Shows Promise In Copper Build-Up Genetic Disease
August 26, 2021
AstraZeneca plc (NASDAQ: AZN) reported high-level results from the FoCus Phase 3 trial evaluating ALXN1840 in Wilson disease. The study met the primary goal of...
Via
Benzinga
Why Did AstraZeneca's Alexion Stop Amyotrophic Lateral Sclerosis Trial?
August 20, 2021
AstraZeneca Inc's (NASDAQ: AZN) newly acquired Alexion division will stop developing a treatment for the neurological disorder amyotrophic lateral sclerosis (ALS) due to...
Via
Benzinga
AstraZeneca's COVID-19 Antibody Cuts Risk Of Symptomatic Disease By 77%
August 20, 2021
A new coronavirus antibody treatment developed by AstraZeneca plc (NASDAQ: AZN) reduced the risk of developing the symptomatic disease by 77% compared to placebo....
Via
Benzinga
Exposures
COVID-19
Facebook Blocks Russia Based Ad Agency Behind COVID-19 Vaccine Smear Campaign
August 12, 2021
Facebook Inc (NASDAQ: FB) removed multiple accounts linked to a mysterious advertising agency operating out of Russia that sought to pay social media influencers to deride...
Via
Benzinga
Exposures
COVID-19
Britain Study Shows Restricted Use Of AstraZeneca COVID-19 Shot Associated With No Clot Cases: Reuters
August 12, 2021
Following a decision to restrict the use of University of Oxford / AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine in those under the age of 40 years, no new cases...
Via
Benzinga
Exposures
COVID-19
AstraZeneca's Forxiga Wins European Approval For Chronic Kidney Disease
August 09, 2021
The European Union has approved AstraZeneca plc’s (NASDAQ: AZN) Forxiga (dapagliflozin) for chronic kidney disease (CKD) in adults with and without type-2...
Via
Benzinga
AstraZeneca' Saphnelo Wins FDA Nod For Systemic Lupus Erythematosus, Marking New Treatment Approval In 10 Years
August 02, 2021
The FDA has approved AstraZeneca Plc's (NASDAQ: AZN) Saphnelo (anifrolumab-fnia) for adult patients with moderate to severe systemic lupus erythematosus (SLE)...
Via
Benzinga
Exposures
Product Safety
AstraZeneca Looking At Potential Options for COVID-19 Vaccine Business: Reuters
July 29, 2021
AstraZeneca plc (NASDAQ: AZN) is reportedly exploring its options for the future of its COVID-19 vaccine business. The Company expects clarity on the matter by the...
Via
Benzinga
Exposures
COVID-19
AstraZeneca Stock Gains As Q2 Earnings Beat Forecasts, Clocks $894M In COVID-19 Vaccine Sales
July 29, 2021
AstraZeneca plc (NASDAQ: AZN) COVID vaccine generated $894 million in sales in Q2. The group added that it shipped about 319 million doses worldwide during 1H of 2021,...
Via
Benzinga
Topics
Earnings
Exposures
COVID-19
Financial
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.